ArticleProceedings of the National Academy of Sciences of the United States of America2006
A purified Bacillus thuringiensis crystal protein with therapeutic activity against the hookworm parasite Ancylostoma ceylanicum.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 104 citations in OpenAlex.
- Bacillus thuringiensis Cry14A family proteins as novel anthelmintics against gastrointestinal nematode parasites.PLoS neglected tropical diseases · 2024Article
- The nematode (Ascaris suum) intestine is a location of synergistic anthelmintic effects of Cry5B and levamisole.PLoS pathogens · 2024Article
- Abundance, distribution, and expression of nematicidal crystal protein genes in Bacillus thuringiensis strains from diverse habitats.International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- Diethylcarbamazine, TRP channels and CaScientific reports · 2022Article
- Insights from the Structure of an Active Form ofToxins · 2022Article
- Efficient and Scalable Process to Produce Novel and Highly Bioactive Purified Cytosolic Crystals from Bacillus thuringiensis.Microbiology spectrum · 2022Article
- Comparison of percutaneous vs oral infection of hamsters with the hookworm Ancylostoma ceylanicum: Parasite development, pathology and primary immune response.PLoS neglected tropical diseases · 2022Article
- An inactivated bacterium (paraprobiotic) expressingOne health (Amsterdam, Netherlands) · 2021Article
- Recombinant Paraprobiotics as a New Paradigm for Treating Gastrointestinal Nematode Parasites of Humans.Antimicrobial agents and chemotherapy · 2021Article
- A new paraprobiotic-based treatment for control of Haemonchus contortus in sheep.International journal for parasitology. Drugs and drug resistance · 2020Article
- Sensory cilia as the Achilles heel of nematodes when attacked by carnivorous mushrooms.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Omics Driven Understanding of the Intestines of Parasitic Nematodes.Frontiers in genetics · 2019Review
- Article
- Bacillus thuringiensis Cry5B protein as a new pan-hookworm cure.International journal for parasitology. Drugs and drug resistance · 2018Article
- Suppressing a plant-parasitic nematode with fungivorous behavior by fungal transformation of a Bt cry gene.Microbial cell factories · 2018Article
- In vivo and in vitro studies of Cry5B and nicotinic acetylcholine receptor agonist anthelmintics reveal a powerful and unique combination therapy against intestinal nematode parasites.PLoS neglected tropical diseases · 2018Article
- The Global State of Helminth Control and Elimination in Children.Pediatric clinics of North America · 2017Review
- A Novel Fucose-binding Lectin from Photorhabdus luminescens (PLL) with an Unusual Heptabladed β-Propeller Tetrameric Structure.The Journal of biological chemistry · 2016Article
- Odanacatib, a Cathepsin K Cysteine Protease Inhibitor, Kills Hookworm In Vivo.Pharmaceuticals (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Crystal (Cry) proteins produced by the soil bacterium Bacillus thuringiensis (Bt) are harmless to vertebrates, but they are highly toxic to insects and nematodes. Their value in controlling insects that destroy crops and transmit human diseases is well established. Although it has recently been demonstrated that a few individual Bt Cry proteins, such as Cry5B, are toxic to a wide range of free-living nematodes, the potential activity of purified Cry proteins against parasitic nematodes remains largely unknown. We report here studies aimed at characterizing in vitro and in vivo anthelminthic activities of purified recombinant Cry5B against the hookworm parasite Ancylostoma ceylanicum, a bloodfeeding gastrointestinal nematode for which humans are permissive hosts. By using in vitro larval development assays, Cry5B was found to be highly toxic to early stage hookworm larvae. Exposure of adult A. ceylanicum to Cry5B was also associated with significant toxicity, including a substantial reduction in egg excretion by adult female worms. To demonstrate therapeutic efficacy in vivo, hamsters infected with A. ceylanicum were treated with three daily oral doses of purified Cry5B, the benzimidazole anthelminthic mebendazole, or buffer. Compared with control (buffer-treated) animals, infected hamsters that received Cry5B showed statistically significant improvements in growth and blood hemoglobin levels as well as reduced worm burdens that were comparable to the mebendazole-treated animals. These data demonstrate that Cry5B is highly active in vitro and in vivo against a globally significant nematode parasite and that Cry5B warrants further clinical development for human and veterinary use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.